Targeting Non-Monoaminergic Pathways in MDD and TRD Treatment

Learn how this critical neurotransmitter is reshaping our understanding of depression, cognition, and mood disorders.
17 hours ago
from: HMP Global Learning Network

Depression, Major depressive disorder, Medicine, STAR*D

More about this

- Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes
Gus Alva, MD, DFAPA, introduces his esteemed colleagues and leads a comprehensive discussion on the complexities of managing major...
from: Psychiatric Times

- Unmet Needs and Limitations in TRD and MDD Treatment
Explore the current challenges in treating major depressive disorder (MDD) in a discussion with Brooke Kempf, MSN, PMHNP-BC, hospitalist at...
from: HMP Global Learning Network